{
    "nctId": "NCT02032563",
    "briefTitle": "Study of the ICG Distribution in Breast Tumours or in Axillary Lymph Nodes of Patients After Neoadjuvant Therapy",
    "officialTitle": "Study of the (Intravenously Injected) Indocyanine Green Distribution in Tumour Bearing Breasts and in Axillary Pieces of Dissection of Patients Who Have Received Neoadjuvant Therapy for Histologically Proven Mammary Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "fluorescence intensity of tumoral lesions, scars and healthy tissues after IV injection of ICG in breast cancer patients after neoadjuvant therapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histopathological diagnosis of mammary cancer who have received neoadjuvant therapy and are candidate, either for tumorectomy, or for mastectomy with complete axillary node dissection,\n* Informed consent form signed.\n\nExclusion Criteria:\n\n* Diagnosis of mammary cancer established, either by tumorectomy, or by \"gross\" biopsy,\n* Age less than18 years old.\n* Inability to give informed consent.\n* History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish.\n* Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland.\n* Documented coronary disease.\n* Advanced renal impairment (creatinine \\> 1,5mg/dl).\n* During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).\n* Pregnancy, breastfeeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}